drugset / Trial / NCT05642325

Vamikibart in Participants With Uveitic Macular Edema

NCT05642325

Phase 3 Completed 256 enrolled Hoffmann-La Roche
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Timeline

Start
2023-03-23
Primary completion
2025-05-07
Completion
2025-12-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Vamikibart Monoclonal antibody Intravitreal

Indications